A detailed history of Susquehanna International Group, LLP transactions in Nkarta, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 10,200 shares of NKTX stock, worth $23,154. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,200
Previous 18,500 44.86%
Holding current value
$23,154
Previous $109,000 57.8%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$5.27 - $10.82 $94,385 - $193,786
-17,910 Reduced 49.19%
18,500 $109,000
Q1 2024

May 07, 2024

BUY
$5.59 - $15.71 $101,318 - $284,743
18,125 Added 99.12%
36,410 $393,000
Q4 2023

Feb 14, 2024

SELL
$1.31 - $6.6 $310,257 - $1.56 Million
-236,838 Reduced 92.83%
18,285 $120,000
Q3 2023

Nov 14, 2023

SELL
$1.39 - $2.29 $15,709 - $25,881
-11,302 Reduced 4.24%
255,123 $354,000
Q2 2023

Aug 11, 2023

BUY
$2.19 - $5.17 $25,877 - $61,088
11,816 Added 4.64%
266,425 $583,000
Q1 2023

May 16, 2023

BUY
$3.37 - $6.3 $756,066 - $1.41 Million
224,352 Added 741.49%
254,609 $903,000
Q4 2022

Feb 14, 2023

SELL
$5.14 - $14.35 $120,486 - $336,378
-23,441 Reduced 43.65%
30,257 $181,000
Q3 2022

Nov 14, 2022

BUY
$12.27 - $18.39 $658,874 - $987,506
53,698 New
53,698 $707,000
Q4 2021

Feb 14, 2022

BUY
$12.79 - $26.88 $110,774 - $232,807
8,661 Added 21.57%
48,812 $749,000
Q3 2021

Nov 15, 2021

SELL
$26.67 - $38.76 $170,581 - $247,908
-6,396 Reduced 13.74%
40,151 $1.12 Million
Q2 2021

Aug 11, 2021

BUY
$23.94 - $36.68 $933,276 - $1.43 Million
38,984 Added 515.46%
46,547 $1.48 Million
Q1 2021

May 17, 2021

SELL
$31.33 - $59.61 $5,044 - $9,597
-161 Reduced 2.08%
7,563 $249,000
Q4 2020

Feb 16, 2021

SELL
$27.03 - $75.62 $41,247 - $115,396
-1,526 Reduced 16.5%
7,724 $475,000
Q3 2020

Nov 16, 2020

BUY
$23.52 - $47.9 $217,560 - $443,075
9,250 New
9,250 $278,000

Others Institutions Holding NKTX

About Nkarta, Inc.


  • Ticker NKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,656,800
  • Market Cap $110M
  • Description
  • Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...
More about NKTX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.